Dimitrije's  Instablog

Send Message
Bachelor of Science in Business Admin and Marketing. Currently working as a private company director.
  • What's in store for CEL-SCI (CVM) 8 comments
    Nov 13, 2009 1:03 AM | about stocks: CVM
    Before you can truly appreciate an opinion piece such as this please make sure you are familiar with the company itself. Do your own DD from reputable verifiable sources.   This way you can appreciate what is being said if it helps you and be able to spot the BS quickly.
    The prediction for Cel Sci share price for the next few weeks or so will be pretty much determined by these three factors or a combination there of. Techinals, Shorts, and News.
    ·         Assuming no news being released of course
    ·         Intermediate trend is bearish. Uptrend has turned sideways, may continue or pullback.
    ·         Most likely short term rally will start to slow then pull back.
    ·         Resistance: 1.79 ± 0.16, 
    ·         Support 1.06 ± 0.09,
    ·         Judgment is that without any news stock will continue to drift downwards probably at ~ -5%/day. I don’t see this stock reaching sub $1.00 levels in the next month or so.
    Shares Short:                                     10,425,800 
    Days To Cover (Short Ratio):       1.4 
    Short % of Float:                               7.43 %
    Short % Increase:                             9.50 %
    % from 52-Week HIGH:                 -55.56 % 
    % from 50 Day MA:                         -4.44 %
    Shares Short -Prior Mo:                 9,520,900
    This is my take CEL-SCI shorts.
    An average investor will generally not short stocks that are under $20.00. These provide low risk of insane loses and it generally means there is a good amount of information regarding the company out there so you can make an informed judgment.
     Trying to understand why somebody would short a stock such as CVM when presented with such high risk is beyond me. The only reason I can see is because a stock such as this is somewhat influenced by bashers and bloggers with personal agendas. Main reason being is that there is just not enough firm information and a lot of information that is available is speculation.   Just look at the amount of bashing posts on message boards. Every other post is full of irrelevant information meant to scare newbies that are researching the stock or to scare the weak ones who are currently holding. 
    The only reason why somebody would spend so much time posting garbage is because they have a vested interest in doing so. It’s by far easier to scare people and bring the stock value down than it is to instill confidence.   Basically the ones shorting are scared that the coverage the company has been getting might bring an influx of people buying and majority of shorts to cover to avoid losses. Therefore causing the price to rise and triggering a squeeze.    The fact that this stock might jump at any given time is just more incentive for them to do so.
    I see the fact that there is so much short interest as a good thing. I foresee a short squeeze happening as soon as the stock reaches above $1.75 ± 0.10 which at the rate this stock has moved could be very soon. I also foresee them getting more desperate and the bashing posts increasing closer we get to that price.
    Following are the news that will cause the stock to rise
    Validation of the facility ONLY
    Stock price will most likely be in the $2.50-$4.50. 
    Reason for the stock going up is the fact that once the facility is validated that means that CEL-SCI can start receiving income. (approx $150,000/day). If there are any contracts announced then the price will of course be higher. 
    The reason it’s not going up thru the roof is that:
    1.       The news has been out for a long time and is partly priced in already
    2.       The validation by itself doesn’t mean income it just means that the company is able to get income.
    Significant news regarding LEAPS-H1N1:
    By this I mean either sick human clinical trials or any kind of official government recognition. Depending on the news the price could quite easily go above $10.00 and possibly end up around $20-$30 (not probable soon but quite possible).
    Reason for this is simple. LEAPS is not a vaccine and is a treatment that boosts body’s own immunity. There are no competitors and at the rate the flu has been affecting people it will be a very good tool for doctors. Income from this would be quite substantial.
    Multikine news
    Again depending on the type of news the share price could jump significantly.   The drug will provide significant income to the company and more concrete the news are the higher the price will go.
    Stocks: CVM
Back To Dimitrije's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (8)
Track new comments
  • Goosie69
    , contributor
    Comments (18) | Send Message
    Whatever the future holds in terms of medical development's inside the company - the high shortrate begs for a short squeeze; at the $1.50 level there is a risk for huge losses for those shorts even on small positve news. Even if we go below $1 the shorts will want to take profits > Support.


    Long CVM since $0.65.
    13 Nov 2009, 06:27 AM Reply Like
  • User 488544
    , contributor
    Comments (2) | Send Message
    Thank you very much. It's this type of opinion that is a pleasure to read. It help a novice like myself very much. Found it on yahoo cvm msg. board. And yes, the bashers you describe are a constant there, although easy to see through and ID. Thanks again, James Michael
    13 Nov 2009, 07:18 AM Reply Like
  • User 480581
    , contributor
    Comment (1) | Send Message
    Great arcticle...QUic question, do you have an opinion on Amex: RNN.
    I appreciate your consideration.




    13 Nov 2009, 08:52 AM Reply Like
  • User 385240
    , contributor
    Comments (2) | Send Message
    Of course, I hope your projections are in the ball park. This, and not to mention the work being done on Rheumatoid Arthritis C-2000, should greatly add to the revenus stream.


    Further, validation of the science may lead to new work on LEAPS such as Breast Cancer.




    13 Nov 2009, 11:17 AM Reply Like
  • M. E. Garza
    , contributor
    Comments (122) | Send Message
    Multikine is a great drug, but I agree that LEAPS shows tremendous potential and is worth getting excited about.
    13 Nov 2009, 06:25 PM Reply Like
  • jay brebner
    , contributor
    Comments (140) | Send Message
    this article is a load of crap. multikine is a definite longshot.
    13 Nov 2009, 09:03 PM Reply Like
  • BioGuy
    , contributor
    Comments (84) | Send Message
    Yeah, even though LEAPS does not describe an actual technology (I could stick two peptides together in my kitchen, that's all the patent claims) and, oh, it's been around for over 10 years.


    The only reason biotech is the biggest victim of hype is because no one understands it. Only an moron would invest on some hack advice.


    By the way, Dimitrje is a fake user written by VFC Stockhouse or Garza, or who really cares. Why don't you fools go hype some other industry.


    On Nov 13 06:25 PM M. E. Garza wrote:


    > Multikine is a great drug, but I agree that LEAPS shows tremendous
    > potential and is worth getting excited about.
    4 Dec 2009, 02:53 AM Reply Like
  • gretel
    , contributor
    Comments (304) | Send Message
    I am married to CVM and as not many of you know it takes time and courage to make "thing's work "and this is why so many of you are
    with wife number 5 and many lost children .
    Listen to Feuerstein-Frankenstein and for sure you will not have
    much money in the future !
    6 Feb 2010, 11:23 PM Reply Like
Full index of posts »
Latest Followers

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.